Solvay Expects Advisory Cmte. Review For Irritable Bowel Agent Cilansetron
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Gastrointestinal Drugs and Drug Safety & Risk Management Advisory Committees are expected to discuss cilansetron at a March 9 joint meeting. The agency extends the Jan. 1 user fee deadline for the NDA by 90 days to April 1.